Investing

Top Analyst Upgrades and Downgrades: Alcoa, Broadcom, Disney, Dow, Lyft, Netflix, Roku, Wingstop, Xilinx and More

Lyft Inc. (NASDAQ: LYFT) was started with a Sell rating at Seaport Global, with the firm noting that it is not for the idea that millennials and future generations are going to all ditch automobiles just for ride-sharing. Another firm named Cross Research, which is a new name in our research universe, reportedly has started Lyft with a Buy rating. The shares closed down 11.8% at $69.01 on Monday and were indicated down another 4% at $66.00 on Tuesday as an officially broken IPO.

Netflix Inc. (NASDAQ: NFLX) was started as Neutral with a $350 price target at Rosenblatt Securities. Netflix closed up 2.9% at $366.96 on Monday, and it has a consensus target price of $382.97.

Pacific Biosciences of California Inc. (NASDAQ: PACB) was downgraded to Equal Weight from Overweight at Stephens.

Quest Diagnostics Inc. (NYSE: DGX) was raised to Buy from Hold at Jefferies.

Roku Inc. (NASDAQ: ROKU) was started as Neutral with a $63 price target at Rosenblatt Securities. It closed up 7% at $69.11 on Monday and has a consensus target price of $67.41.

Ryanair Holdings PLC (NASDAQ: RYAAY) was downgraded to Hold from Buy at HSBC.

Teledyne Technologies Inc. (NYSE: TDY) was started with an Outperform rating and assigned a $265 target price (versus a $240.21 close) at Cowen.

Walt Disney Co. (NYSE: DIS) was started as Buy with a $150 price target at Rosenblatt Securities. After closing up 1.3% at $112.51 on Monday, it was indicated to open up 0.6% at $113.16, and the consensus target price is $126.45.

Wingstop Inc. (NASDAQ: WING) was downgraded to Neutral from Buy at Guggenheim.

Xilinx Inc. (NASDAQ: XLNX) was reiterated as Overweight at KeyBanc Capital Markets, which raised the price target to $145 from $140. Shares closed up 2.3% at $129.73, in a 52-week range of $62.54 to $130.57.

One speculative reiterated call was in shares of Entasis Therapeutics Inc. (NASDAQ: ETTX) with its Outperform rating and $19 target price (versus a $6.40 close) at Wedbush Securities. The firm noted that two Phase 3 studies are on track to start in 2019 and that the clinical development for Entasis’s differentiated abx pipeline remains on track. It expects full Phase 1 data for ETX0282CPDP in mid-2019, and Phase 3 studies are set to start for ETX2514SUL in carbapenem-resistant Acinetobacter (Q2-2019) and zoliflodacin in uncomplicated gonorrhea (mid-2019). Entasis has only an $84 million market cap, and its 52-week trading range is $3.97 to $13.70.

One restaurant franchise firm could offer 50% upside if the most aggressive analyst covering it is proven correct.

Jefferies has its top growth picks for big upside ahead in 2019.

With tax season upon us, here are 17 investment strategies that will help to lower your taxes.

Monday’s top analyst calls included Amazon.com, CarMax, Celgene, Chevron, Exxon Mobil, Lyft, FedEx, Peabody Energy, UPS, Wells Fargo and many more.